Authors: Gabrielle Gimenes Lima and Anderson Rossatto (FEBRAF, Brazil).
When properly trained and qualified, the community pharmacist can collaborate
in the identification and management of cardiovascular risk factors, contributing
to an increase in the quality of life of patients and a reduction in the number of
surgeries, hospitalizations and conditions of physical inactivity.
In order for drug therapy to be effective in the treatment of hypertension,
dyslipidemia and diabetes and to prevent cardiovascular complications, in
addition to the proper use of medications, it is important that
non-pharmacological conducts are practiced, which imply changes in habit.
Education is part of health care, so the pharmacist should not give up
educational actions that aim to reduce cardiovascular risk factors and improve
the results of pharmacotherapy.
One of the habit changes that has relevance in terms of cardiovascular health is
smoking cessation. Data from the World Health Organization (WHO) indicate
that smoking causes more than seven million deaths annually worldwide and
shows a relationship with numerous diseases, among which CVDs, cancers and
chronic obstructive respiratory diseases stand out.2
The community pharmacist can assist in the identification of the everyday
circumstances that characterize "triggers" for smoking and in the establishment
of strategies that aim to overcome such situations, with the objective of stopping
smoking and preventing relapses. From a structured approach and specific
, one can assess the patient's degree of dependence on nicotine,
check whether there are indications or contraindications for pharmacological
treatment, classify the individual's motivational level with a view to quitting
smoking and prepare a therapeutic follow-up plan for the patient. , involve other
health professionals, when necessary 4 Nicotine-based anti-tobacco drugs are
non-prescription drugs and can be prescribed in Brazil by the pharmacist 5
SILVA EV, et al. O papel do farmacêutico comunitário no
aconselhamento ao paciente. Farmacoterapêutica, 2008; 13(4-5): 1-3.
GOYATÁ T, et al. Impacto do programa de apoio ao tabagista de um
município do sul de Minas Gerais, Brasil. Ciencia y Enfermeria, 2014;
REICHERT J, et al. Diretrizes para cessação do tabagismo. Jornal
Brasileiro de Pneumologia, 2008; 34(10): 845-880.
BRASIL. Ministério da Saúde. Instituto Nacional do Câncer.
Coordenação de ações estratégicas, Divisão de controle do tabagismo,
2013 – Protocolo Clínico e Diretrizes Terapêuticas de Dependência à
Nicotina, Rio de Janeiro. 2013b.
BRASIL. Conselho Federal de Farmácia. Resolução n° 586, de 21 de
Julho de 2013. 2013a.